Foley Hoag achieved a complete victory in defense of Alexion Pharmaceuticals in a trade secret misappropriation case filed by Amyndas Pharmaceuticals, with entry of final judgment by the United States District Court for the District of Massachusetts in Alexion’s favor and dismissal with prejudice of Amyndas’ only remaining claim for breach of contract.

This follows an initial victory in March when Judge Leo T. Sorokin entered an order that adopted a magistrate judge's recommendation to grant Alexion's motion for summary judgment on the majority of the claims asserted by Amyndas in its lawsuit.

This case is one of an increasing number of trade secret cases being brought after failed deal negotiations.

Amyndas alleged that Alexion and its C3 collaboration partner Zealand Pharma U.S. improperly used information about C3 complement inhibitors that they learned through separate early-stage business discussions with Amyndas.

In particular, Amyndas alleged that Alexion used information it had learned about C3 from Amyndas to enter into the collaboration with Zealand’s Danish parent. Amyndas asserted claims under both the state and federal trade secret statutes as well as breach of contract, unfair competition under M.G.L. Chapter 93A, tortious interference, unjust enrichment and civil conspiracy against Alexion and its collaboration partner.

On December 10, 2025, Magistrate Judge Jennifer Boal issued a report recommending that the court grant Alexion's motion for partial summary judgment in its entirety. The magistrate judge found that Amyndas failed to meet its burden of identifying with sufficient specificity most of its alleged trade secrets, failed to establish a triable issue of fact regarding misuse by Alexion of any of the alleged trade secrets, and failed to establish sufficient evidence from which a jury could reasonably infer that Alexion’s conduct caused harm to Amyndas as required to support its c. 93A unfair competition claim.

Finally, the report recommended that Alexion be granted summary judgment on Amyndas’s claims for tortious interference, civil conspiracy, unjust enrichment, and breach of the implied covenant of good faith and fair dealing.

On March 11, 2026, Judge Sorokin adopted the report in full. In doing so, the court underscored that Alexion’s use of Amyndas’s alleged trade secrets was within the scope of permissible uses set forth in the confidential disclosure agreement.

On June 16, 2026, Judge Sorokin entered an order reflecting that Amyndas agreed to dismiss its only remaining claim, breach of contract, with prejudice.

The Foley Hoag team representing Alexion was led by partners Kenneth Leonetti, Barbara Fiacco and Urszula Nowak.